Macimorelin Acetate (EP-1572), an orally active growth hormone (GH) secretagogue and a ghrelin receptor (GHSR) agonist, stimulates GH release. It is utilized in research focusing on adult growth hormone deficiency (AGHD) and Cancer Anorexia-Cachexia Syndrome (CACS).

NFATc1-IN-1 (0、0.5、1.0、1.5、2.0、2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM.[1]
NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1.[1]